Anaplastic Thyroid Cancer Pipeline 2025

With anaplastic thyroid cancer increasingly prevalent worldwide and contributing to comorbidities like diabetes, cardiovascular disease, and other cancers, there is a rising demand for safer and more effective treatments. According to DelveInsight, the anaplastic thyroid cancer pipeline involves 8+ pharmaceutical and biotech companies developing 8+ therapeutic candidates. These therapies are at various stages of clinical and preclinical development, highlighting substantial innovation and dedication to tackling this critical public health challenge.

DelveInsight’s report, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” offers a comprehensive and strategic review of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving anaplastic thyroid cancer therapeutics market and the breakthroughs shaping its future.

Explore the Cutting-Edge Landscape of Anaplastic Thyroid Cancer Drug Development @ https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:

• In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).

• In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.

• In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).

• In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.

• In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.

• In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.

• In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.

• In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.

Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report

• DelveInsight’s Anaplastic Thyroid Cancer pipeline report highlights a dynamic landscape with 8+ active companies developing 8+ therapeutic candidates for the treatment of anaplastic thyroid cancer.

• In August 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AIC100, an investigational CAR T-cell therapy targeting ICAM-1, for the treatment of recurrent ATC.

• Leading companies in the anaplastic thyroid cancer space—including Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others—are actively developing new therapies to enhance treatment options.

• Promising pipeline candidates in development include Sapanisertib, HLX208, and several others.

Anaplastic Thyroid Cancer Overview:

Anaplastic thyroid cancer (ATC) is a rare and highly aggressive type of thyroid cancer. The thyroid gland, located at the front of the neck just below the Adam’s apple, produces essential hormones for the body. Unlike other thyroid cancers, ATC spreads quickly to other parts of the body. It primarily affects people over the age of 60 and is also referred to as anaplastic thyroid carcinoma.

Although uncommon, ATC accounts for only 1% to 2% of all thyroid cancer cases, with approximately one to two diagnoses per million people annually in the United States. The disease often starts as a lump in the neck, and as the tumor enlarges, it can press on the vocal cords, causing hoarseness, or obstruct the windpipe, making breathing difficult. In some instances, small tumors may go unnoticed for a period of time.

Download the Anaplastic Thyroid Cancer sample report to know in detail about the Anaplastic Thyroid Cancer treatment market

Anaplastic Thyroid Cancer Pipeline Analysis

The Anaplastic Thyroid Cancer pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Anaplastic Thyroid Cancer Market.

• Categorizes Anaplastic Thyroid Cancer therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Anaplastic Thyroid Cancer drugs under development based on:

  • Stage of development

  • Anaplastic Thyroid Cancer Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Anaplastic Thyroid Cancer Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Anaplastic Thyroid Cancer Licensing agreements

  • Funding and investment activities supporting future Anaplastic Thyroid Cancer market advancement.

Unlock key insights into emerging Anaplastic Thyroid Cancer therapies and market strategies here:https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Anaplastic Thyroid Cancer Emerging Drugs

Sapanisertib – Takeda

Sapanisertib is a dual TORC1/2 inhibitor designed to target a critical survival pathway in tumor cells harboring KEAP1/NRF2 mutations, which are frequently observed in many patients with various solid tumors. The drug has shown promising results as a monotherapy in patients with relapsed or treatment-resistant NRF2-mutated squamous non-small cell lung cancer (NSCLC). In preclinical studies, sapanisertib exhibited distinct anti-tumor activity compared to TORC1-specific rapalogs in NRF2-mutated squamous NSCLC models.

HLX208 – Shanghai Henlius Biotech

HLX208 is a small-molecule inhibitor designed to target the BRAF V600E mutation, with potential applications across multiple solid tumors. The therapy may be combined with Henlius’s proprietary EGFR- or PD-1-targeting antibodies, supporting the development of a strong, innovative, and differentiated oncology portfolio for diverse cancer indications.

Anaplastic Thyroid Cancer Pipeline Therapeutic Assessment

Anaplastic Thyroid Cancer Assessment by Product Type

• Mono

• Combination

• Mono/Combination

Anaplastic Thyroid Cancer By Stage

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Anaplastic Thyroid Cancer Assessment by Route of Administration

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Anaplastic Thyroid Cancer Assessment by Molecule Type

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Anaplastic Thyroid Cancer therapies and key Anaplastic Thyroid Cancer companies

Table of Contents

1. Report Introduction

2. Executive Summary

3. Anaplastic Thyroid Cancer Current Treatment Patterns

8. Anaplastic Thyroid Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

8. Anaplastic Thyroid Cancer Late-Stage Products (Phase-III)

7. Anaplastic Thyroid Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

8. Inactive Products

11. Dormant Products

12. Anaplastic Thyroid Cancer Discontinued Products

13. Anaplastic Thyroid Cancer Product Profiles

18. Anaplastic Thyroid Cancer Key Companies

15. Anaplastic Thyroid Cancer Key Products

18. Dormant and Discontinued Products

17. Anaplastic Thyroid Cancer Unmet Needs

18. Anaplastic Thyroid Cancer Future Perspectives

19. Anaplastic Thyroid Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Anaplastic Thyroid Cancer pipeline reports offerings: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/